Collaboration to develop, manufacture and commercialize next-generation selective PARP1 inhibitor HRS-1167, with option to develop, manufacture and comme...
The co-primary endpoints of the LIBRA trial were mite eradication (mite density of 0 mites per lash) and complete collarette cure (collarette score of 0) a...
Indicated in combination with chemotherapy for 1st line treatment and as monotherapy for patients with disease progression on or after platinum containing ...
In a rapidly evolving world where data and artificial intelligence have become paramount, BioAsia 2024 presents a theme that transcends traditional boundar...
Lunit SCOPE IO pivotal in first phase III trial successfully showing the efficacy of immunotherapy + chemotherapy for NSCLC patients with EGFR or ALK mut...
– Risk of death was reduced by 53% in patients treated with enfortumab vedotin plus pembrolizumab compared to chemotherapy – – Enfo...
To support emerging precision therapies and improve patient outcomes by increasing access to reliable genomic testing needed to match patients with targete...
ERS Genomics Limited ('ERS') completes licensing agreement with Syngene International, India's leading Contract Research, Development and Manufacturing Org...
Dr. Ali will be spearheading all aspects of MHTC’s operations, ensuring its commitment to facilitating and promoting the nation’s healthcare tr...
Fezolinetant is an investigational nonhormonal treatment for vasomotor symptoms (VMS) associated with menopause More than half of women ages 40 to 64 wor...
Everest Medicines announced that its licensing partner, Pfizer Inc. (NYSE: PFE) has received approval from the U.S. Food and Drug Administratio...
In conjunction with breast cancer awareness month, the Malaysia Healthcare Travel Council (MHTC) together with Subang Jaya Medical Centre, organised a thou...
Indivior PLC (LSE/Nasdaq: INDV), a leading addiction treatment company, today announced that it has gained exclusive global rights to develop, manufacture,...
SS Innovations International, Inc. (the “Company” or “SS Innovations”) (OTC: SSII), a developer of innovative surgical robotic tech...
© 2026 Biopharma Boardroom. All Rights Reserved.
